EIK1005
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for EIK1005, covering 2026-04-08 to 2026-04-08. Get the full timeline:
Most recent: Clinical Trial Update: EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors [Phase 1, Phase 2]